sur ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics is preparing for its General Assembly on June 30, 2026
On June 9, 2026, ABL Diagnostics, a company specializing in molecular biology tests, announced that its Ordinary and Extraordinary General Meeting will be held on June 30 in Paris. Shareholders will vote on the 2025 annual financial statements. The preliminary notice, including the agenda and voting procedures, was published on May 22, 2026, in the BALO (Bulletin des Annonces Légales Obligatoires).
Documents related to this meeting are available on the ABL Diagnostics website. The company, based in Woippy and listed on Euronext Paris, offers a range of solutions such as DNA genotyping and PCR. Its product portfolio includes HIV, SARS-CoV-2, and other diseases. ABL Diagnostics is also involved in a strategic agreement with CDL Pharma.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABL DIAGNOSTICS